

Oppose Additional Cuts to Medicare Part B

BIO opposes CMS's recently proposed Part B Drug Payment Model, which:

- Threatens patient access to needed therapies; especially in rural areas and/or by community-based providers by slashing reimbursement rates to effectively ASP+0%
- Forces patients to travel farther to receive care in a potentially higher-cost setting
- Was developed without consideration of the potential impact on patients
- Patients receiving Part B drugs tend to be the sickest, most vulnerable patients
- ASP is working and has controlled the growth of drug spending since 2006 which was previously increasing at a rapid rate
- Sequester has already reduced payments in Part B

Senate Innovation Initiative / Drug Development, Discovery, & Delivery Reforms

BIO looks forward to working with Congress to enact these necessary reforms

- Embrace precision medicine/genomics through regulatory science
- Patient-centric approaches to drug development are essential
- Improve patient access while sustaining incentives for innovation
- Allow the regulatory process to keep up with advances in scientific discovery

Target Abuses of the US Patent System While Protecting Innovation

BIO supports a measured, thoughtful approach to patent litigation reform

- Strong intellectual property protection is the lifeblood of the biotechnology industry
- Investing in biotech is expensive and risky and product development depends heavily on licensing, partnering, and access to capital – strong patent protection is critical
- Halting abuses of the IPR process, an administrative patent challenge, is a top priority
- BIO urges Congress to proceed thoughtfully and deliberately on patent reform legislation

Changing the Medicare Part D Program Can Negatively Impact Patients

BIO opposes changing the incentives of the Medicare D Program

- Medicare Part D continues to ensure seniors have access to pharmacy drugs
- Part D keeps overall costs to beneficiaries and the government down
- Competitive, market-oriented negotiations between plans, PBMs, and manufacturers are critical to this success
- 90% of beneficiaries are satisfied with the program

Support full Appropriations for Key Areas Critical to Discovery & Innovation

BIO supports full appropriations for NIH, Project BioShield SRF & CARB Initiative

- NIH spurs key discovery in an era of genomic health and personalized medicine and BIO supports a budget of at least **\$34.5B** and opposes additional cuts.
- Full appropriations are needed to BARDA, Project BioShield & CARB Initiative to spur discovery and development of products designed to battle emerging security threats.

Support a Federal, Science-Based GMO Food Labeling Solution

BIO supports a labeling solution that informs consumers & provides consistency

- Consumers' Right-To-Know is important and voluntary labels, such as organic or "non GMO," are already widespread in the marketplace
- State-by-state food labeling challenges needlessly undermine consumer confidence
- Industry supports greater public education and engagement around GMOs
- Support and urge Senators to continue to work with industry to find a solution